Kiniksa Pharmaceuticals (KNSA)
US Market

Kiniksa Pharmaceuticals (KNSA) Financial Statements


Kiniksa Pharmaceuticals Financial Overview

Kiniksa Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $3.271; its P/E ratio is 5.09; Kiniksa Pharmaceuticals is scheduled to report earnings on October 30, 2023, and the estimated EPS forecast is $-0.17. See an overview of income statement, balance sheet, and cash flow financials.
Jun 23Mar 23Dec 22Sep 22Jun 22
Income Statement-
Total Revenue$ 54.49M$ 48.34M$ 61.88M$ 99.14M$ 26.97M
Gross Profit$ 63.77M$ 41.31M$ 47.65M$ 87.58M$ 21.94M
EBIT$ -1.24M$ -9.36M$ 7.30M$ 46.41M$ -19.37M
EBITDA$ -1.79M$ -9.83M$ 7.70M$ 46.91M$ -18.72M
Net Income Common Stockholders$ 14.97M$ -12.27M$ 4.46M$ 224.09M$ -19.98M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 184.99M$ 187.49M$ 190.61M$ 200.72M$ 138.21M
Total Assets$ 484.33M$ 442.86M$ 459.67M$ 459.95M$ 210.58M
Total Debt$ 13.52M$ 5.62M$ 5.92M$ 6.71M$ 4.61M
Net Debt$ -171.47M$ -181.88M$ -184.69M$ -194.01M$ -133.59M
Total Liabilities$ 72.68M$ 52.77M$ 459.66M$ 75.94M$ 57.08M
Stockholders Equity$ 411.65M$ 390.10M$ 396.14M$ 384.01M$ 153.49M
Cash Flow-
Free Cash Flow$ -3.78M$ -4.29M$ -11.53M$ 62.03M$ -7.94M
Operating Cash Flow$ -3.74M$ -4.27M$ -11.58M$ 62.05M$ -7.82M
Investing Cash Flow$ 35.53M$ -37.92M$ -42.66M$ 19.04M$ 38.27M
Financing Cash Flow$ 158.00K$ 90.00K$ 1.19M$ 361.00K$ 542.00K
Currency in USD

Kiniksa Pharmaceuticals Earnings and Revenue History

Kiniksa Pharmaceuticals Debt to Assets

Kiniksa Pharmaceuticals Cash Flow

Kiniksa Pharmaceuticals Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis